



Post Authorisation Assessments

Carprox vet 100 mg Tablets for Dogs

Vm 01656/4013

•	11 January 2024	Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex.
•	16 June 2023	Change to comply with Ph. Eur. reflect compliance with the Ph. Eur. by removing reference to the internal test method and test method number. (NI)
•	07 June 2023	Submission of an updated certificate of suitability. (NI)
•	24 February 2023	Change to comply with Ph. Eur. reflect compliance with the Ph. Eur. by removing reference to the internal test method and test method number.
•	24 February 2023	Change to comply with Ph. Eur. reflect compliance with the Ph. Eur. by removing reference to the internal test method and test method number.
•	28 December 2022	Updated certificate of suitability from an already approved manufacturer.
•	08 March 2022	Minor change to an approved test procedure for the active substance.
•	16 December 2021	Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer.
•	12 November 2021	Minor changes to an approved test procedure of the finished product.
•	22 April 2020	Minor change in the manufacturing process of the finished product. Minor change in the manufacturing process of the finished product.
•	19 March 2020	Addition of a manufacturer responsible for batch release including batch control/testing. Addition of a manufacturing site of the finished product.
•	16 December 2019	Deletion of manufacturing site for a finished product. Addition of a secondary packaging site of the finished product. Addition of a primary packaging site of the finished product.
•	10 December 2019	Submission of a new Ph. Eur. certificate of suitability for an active substance from a new manufacturer.
•	07 November 2019	Change in the manufacturer of a starting material used in the manufacturing process of the active substance.
•	11 June 2019	Change in the contact details of the QPPV of an existing pharmacovigilance system as described in the DDPS.
•	10 May 2017	Minor change to the restricted part of an Active Substance Master File.

•	04 December 2015	Deletion of a manufacturing site.
•	06 August 2015	Renewal – UK as CMS.
•	08 September 2014	Change in the manufacturing process of the finished product.
•	16 May 2014	Changes to the manufacturing process for the active substance.
•	26 September 2013	Change of distributor.
•	20 June 2013	Change of product name from 'Rycarfa 100mg Tablets for Dogs' to 'Carprox vet 100mg Tablets for Dogs'.
•	11 February 2013	To update the ASMF for an already approved ASM.
•	23 November 2012	Addition of a manufacturing site responsible for primary and secondary packaging. Increase of shelf life from 2 to 3 years.
•	20 April 2011	Repeat Use Comm – UK as CMS.

•	24 February 2023	Change to comply with Ph. Eur. reflect compliance with the Ph. Eur. by removing reference to the internal test method and test method number.
•	28 December 2022	Updated certificate of suitability from an already approved manufacturer.
•	08 March 2022	Minor change to an approved test procedure for the active substance.
•	16 December 2021	Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer.
•	12 November 2021	Minor changes to an approved test procedure of the finished product.
•	22 April 2020	Minor change in the manufacturing process of the finished product. Minor change in the manufacturing process of the finished product.
•	19 March 2020	Addition of a manufacturer responsible for batch release including batch control/testing. Addition of a manufacturing site of the finished product.
•	16 December 2019	Deletion of manufacturing site for a finished product. Addition of a secondary packaging site of the finished product. Addition of a primary packaging site of the finished product.
•	10 December 2019	Submission of a new Ph. Eur. certificate of suitability for an active substance from a new manufacturer.
•	07 November 2019	Change in the manufacturer of a starting material used in the manufacturing process of the active substance.
•	11 June 2019	Change in the contact details of the QPPV of an existing pharmacovigilance system as described in the DDPS.
•	10 May 2017	Minor change to the restricted part of an Active Substance Master File.
•	04 December 2015	Deletion of a manufacturing site.
•	06 August 2015	Renewal – UK as CMS.
•	08 September 2014	Change in the manufacturing process of the finished product.
•	16 May 2014	Changes to the manufacturing process for the active substance.
•	26 September 2013	Change of distributor.
•	20 June 2013	Change of product name from 'Rycarfa 100mg Tablets for Dogs' to 'Carprox vet 100mg Tablets for Dogs'.
•	11 February 2013	To update the ASMF for an already approved ASM.
•	23 November 2012	Addition of a manufacturing site responsible for primary and secondary packaging. Increase of shelf life from 2 to 3 years.
•	20 April 2011	Repeat Use Comm – UK as CMS.